We’re thrilled to announce a major milestone for Cure51: a strategic collaboration with Servier to uncover new therapeutic targets in glioblastoma and develop new treatments derived from exceptional survivors’ biology.
This partnership combines Cure51’s unique international global cohort of exceptional glioblastoma survivors and proprietary discovery platform with Servier’s R&D and drug-development expertise, aiming to identify and advance new therapeutic targets. It marks Cure51’s first research partnership with a pharmaceutical company, with Cure51 eligible to receive up to €442 million per target in potential milestone payments.
Claude Bertrand, Executive Vice-President, Research & Development, Servier
“By combining Cure51’s unique insights derived from exceptional glioblastoma survivors with our deep R&D capabilities, we are uniquely positioned to translate groundbreaking biological mechanisms into potential new therapies for patients.”
Nicolas Wolikow, our Co-founder and CEO
“By studying the rare patients who survive glioblastoma, Cure51 has built a resource that exists nowhere else: a rigorously curated, global database of exceptional survivors. Together with Servier, we can use this resource to reveal biological insights and potential targets that conventional approaches may overlook.”
This strategic collaboration marks an important step in bringing exceptional survivor biology into drug discovery. Until All Survive.
